Caffeine Consumption and Cataract Prevention

Sponsor
Vienna Institute for Research in Ocular Surgery (Other)
Overall Status
Recruiting
CT.gov ID
NCT05194696
Collaborator
(none)
12,000
1
60
200

Study Details

Study Description

Brief Summary

Effect of peroral caffeine consumption on the delay of cataract onset.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Questionnaire

Detailed Description

Several experimental studies have shown that caffeine inhibits cataract development by scavenging reactive oxygen species. Evidence from epidemiological studies, however, is controversial. Varma et al., found that the incidence of cataract blindness in humans was significantly lower in groups consuming higher amounts of coffee in comparison to the groups with lower coffee intake. Moreover, Rautiainen et al. showed that the dietary total antioxidant capacity including coffee of middle-aged and elderly women was inversely associated with the risk of age-dependent cataract. Another population-based study involving the population residing in Beaver Dam, Wisconsin, did not find a meaningful association between 10-year cumulative incidence of cataract and the amount of caffeine intake.

Although cataracts can be surgically removed, barriers that prevent access to surgery are a problem in many countries. Moreover, no prophylactic treatments are currently available to prevent the onset of cataract. Yet estimates indicate that a delay of only 10 years in the onset of cataract could reduce the need for cataract surgery by as much as 50%.

The present study aims to investigate whether peroral caffeine consumption on a regular daily basis for a significant period of time and sufficient dose delays cataract development.

12000 eyes of 6000 patients will be included into this study. Patient will have to fill out a questionnaire for caffeine consumption habits during lifetime and risk factors for cataract development. Further, a complete ophthalmic examination, cataract grading, refraction, visual testing, and biometry will be performed.

Study Design

Study Type:
Observational
Anticipated Enrollment :
12000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The Impact of Caffeine Consumption on Preventing Cataract
Actual Study Start Date :
Sep 1, 2020
Anticipated Primary Completion Date :
Sep 1, 2024
Anticipated Study Completion Date :
Sep 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Caffeine questionnaire

A questionnaire concerning caffeine habits will be handed out to the patients

Behavioral: Questionnaire
Patients have to answer a questionnaire about their caffeine consumption habits during lifetime

Outcome Measures

Primary Outcome Measures

  1. Caffeine consumption [48 months]

    Caffeine consumption will be assessed using a questionnaire concerning the caffeine drinking habits

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 105 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • age older than 21 years

  • cataract

Exclusion Criteria:
  • age younger than 21 years

Contacts and Locations

Locations

Site City State Country Postal Code
1 Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital Vienna Vienna Austria 1140

Sponsors and Collaborators

  • Vienna Institute for Research in Ocular Surgery

Investigators

  • Principal Investigator: Oliver Findl, MD, Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital Vienna

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Prim. Prof. Dr. Oliver Findl, MBA, Principal Investigator, Vienna Institute for Research in Ocular Surgery
ClinicalTrials.gov Identifier:
NCT05194696
Other Study ID Numbers:
  • CaffQuest
First Posted:
Jan 18, 2022
Last Update Posted:
Jan 31, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Prim. Prof. Dr. Oliver Findl, MBA, Principal Investigator, Vienna Institute for Research in Ocular Surgery
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 31, 2022